Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment.
Explore this paper's citation graph
Summary
Two patients with NSCLC receiving conventional chemotherapy and alternative treatment with gefitinib or erlotinib as second-line therapy are described.
- Type
- article
- Published
- 2014-10-27
- Cited by
- 4
- References
- 10
- Access
- Open access
- OpenAlex
- https://openalex.org/W2184487997
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:38775604
Keywords
Gefitinib, Erlotinib, Medicine, Lung cancer, Epidermal growth factor receptor
References
- Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype.
- Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment
- KL‐6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non‐small cell lung cancer
- Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease.
- Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib.
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
- Erlotinib in previously treated non-small-cell lung cancer.
- Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
- Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
- [Satisfactory outcome with erlotinib after failure with gefitinib in a patient with meningeal carcinomatosis secondary to non-small cell lung cancer].
- Epidermal growth factor receptor (EGFr) expression in nonsmall cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype
Cited by
- 10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient
- Extensive-disease small cell lung cancer, multiple relapses, five lines of therapy and more than 10-year survival
- Maintained Complete Response and Long-Term Survival in Epidermal Growth Factor Receptor Mutated Metastatic Non-Small Cell Lung Cancer with Erlotinib
- Long-Term Outcomes in Patients with EGFR Positive Lung Adenocarcinoma and Subgroup Analysis Based on Presence of Liver Metastases
Related papers
- Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus
- Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
- Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer
- Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
- Three Cases of Long-Lasting Tumor Control with Erlotinib after Progression with Gefitinib in Advanced Non-Small Cell Lung Cancer
- Sequential responses of adenocarcinoma of the lung to erlotinib after gefitinib in never smoker Korean woman.
- A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
- Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
- The effect of erlotinib on EGFR and downstream signaling in oral cavity squamous cell carcinoma